EquityZen Growth Technology Fund LLC - Series 2035
Raised
$250K
Investors
20
Min Invest
$10,000
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2035 is a Delaware pooled investment fund filed February 5, 2025, that raised $250K from 20 investors under Rule 506(b) and Section 3(c)(1). The vehicle is part of EquityZen's pre-IPO secondary platform, with a $10K minimum investment and managed by EquityZen Advisors and Phil Haslett.
This pre-IPO pooled fund uses the standard 506(b) and 3(c)(1) exemption structure typical of private secondary platforms. The $10K minimum and $250K raise across 20 investors ($12.5K average check) reflects EquityZen's retail-accessible model for accessing late-stage private company shares, consistent with other series vehicles in their platform.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
